This highlights a potential drug repurposing opportunity, where CETP inhibitors, which are currently in clinical trials for cardiovascular disease, can be combined with SGLT2 inhibitors to create a combination therapy to treat type 2 diabetes. This evidence concerns the gene SLC5A2 and cardiovascular disorder.